Complex Psoriasis Patients and Challenging Areas to Treat
| Overview / Abstract: |
Areas of plaque psoriasis that are particularly challenging to treat are more common than previously thought, and these areas may not respond as well to traditional treatment approaches. Moreover, they are associated with lower patient quality of life. Clinicians can provide valuable patient-centered care for these psoriasis manifestations by facilitating discussions about treatment goals and formulating individualized approaches using one or more agents from the diverse therapeutic armamentarium for psoriasis. This case-based activity addresses complex scenarios in psoriasis, including challenging areas, severe disease, and other complexities. Clinical decision points and video-based discussion from a dermatologist and nurse practitioner throughout the activity address the burden of psoriasis, its impact on quality-of-life, and available approaches to challenging areas and severe disease. |
|
Expiration |
Apr 24, 2021 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Podcast, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 |
|
Accreditation |
ACCME |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Anthony Fernandez, MD, PhD Lakshi M. Aldredge, MSN, ANP-BC, DCNP |
|
Activity Specialities / Related Topics |
Dermatology, Education / Teaching, Family Medicine, Internal Medicine, Primary Care, Rheumatology / Arthritis |
|
Sponsors / Supporters / Grant Providers |
Sponsored by Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning. Supported by educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation. |
|
Keywords / Search Terms |
ACHL CME, psoriasis, scalp, palmoplantar, methotrexate, cyclosporine, acitretin, Apremilast, phosphodiesterase- 4 inhibitor, Adalimumab, etanercept, infliximab, TNF-1 inhibitors, ustekinumab, IL-12/23 antagonist, ixekizumab, secukinum, IL-17A inhibitors, brodalumab, IL-17 receptor inhibitor, guselkumab, IL-23 inhibitor, Dermatology, Purdue, ACHL, Celgene, Novartis, biologics, Fernandez, Aldredge Free CE CME Live CE CME |
|